Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement GrantGlobeNewsWire • 02/24/26
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of DirectorsGlobeNewsWire • 02/19/26
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHLGlobeNewsWire • 01/21/26
Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being IgnoredSeeking Alpha • 01/16/26
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune DiseaseGlobeNewsWire • 11/12/25
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/12/25
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®GlobeNewsWire • 11/03/25
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in NovemberGlobeNewsWire • 10/30/25
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate UpdateGlobeNewsWire • 10/16/25
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025GlobeNewsWire • 08/25/25
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business HighlightsGlobeNewsWire • 08/06/25
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/28/25
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual MeetingGlobeNewsWire • 05/13/25
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business HighlightsGlobeNewsWire • 05/08/25
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual MeetingGlobeNewsWire • 04/28/25
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerGlobeNewsWire • 04/08/25
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 03/31/25
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/24/25
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceGlobeNewsWire • 02/20/25
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.GlobeNewsWire • 01/29/25
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/12/24
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewsWire • 11/11/24
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of DirectorsGlobeNewsWire • 10/22/24
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/10/24